Investors remain leery of the biotech industry

Oh, those fickle biotech investors. In Vivo says that biotech investors haven't proven to be very bullish about the money that pharma companies are pumping into emerging developers through new collaborations. To make its point, In Vivo highlights a series of big-dollar deals at public biotech companies and their subsequent drop in stock price.

To be fair, notes In Vivo, the equities market has been shaken up recently. But the good partnership news should have overcome the Wall Street jitters, insists the blog. It's all a sign that the market no longer cares about such market validations.

- read the analysis in In Vivo

Related Articles:
Pharma noshes at the biotech buffet. Report
VC adds billions in its pursuit of biotech ventures. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Biotech stocks surge as investors anticipate buyouts. Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.